Opthea Limited or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: Opthea vs. Amphastar

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Amphastar Pharmaceuticals, Inc. consistently reported higher SG&A expenses compared to Opthea Limited. Amphastar's expenses grew from approximately $40 million in 2014 to over $80 million by 2023, reflecting a 100% increase. In contrast, Opthea's SG&A costs surged from around $2.7 million to $41.9 million in the same period, marking a staggering 1,450% rise.

While Amphastar's expenses are higher in absolute terms, Opthea's rapid increase suggests aggressive expansion or investment in administrative capabilities. Notably, 2023 saw Opthea's expenses peak, possibly indicating strategic shifts or market challenges. Missing data for 2024 suggests caution in future projections. Investors and analysts should consider these trends when evaluating operational efficiency and strategic direction.